Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?Defense World · Oct 1, 2026
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis SuppurativaGlobeNewsWire · Sep 30, 2026
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare ConferenceGlobeNewsWire · Sep 3, 2026
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialGlobeNewsWire · Aug 27, 2026
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 7, 2026
Corvus Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat · Aug 6, 2026Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.16 | -$0.19 | Miss |
| May 7, 2026 | -$0.14 | -$0.15 | Miss |
| Mar 12, 2026 | -$0.14 | -$0.15 | Miss |
| Nov 4, 2025 | -$0.14 | -$0.12 | Beat |
| Aug 7, 2025 | -$0.13 | -$0.10 | Beat |
| May 8, 2025 | -$0.13 | -$0.13 | Beat |